Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Body Weight

lenalidomide has been researched along with Body Weight in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Gonsalves, WI; Lam, S; M Saunders, I; Momper, JD; Salama, E; Tzachanis, D1
Chen, N; Connarn, JN; Gao, Y; Hwang, R; Palmisano, M1
Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E1

Other Studies

3 other study(ies) available for lenalidomide and Body Weight

ArticleYear
Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing.
    The Annals of pharmacotherapy, 2023, Volume: 57, Issue:1

    Topics: Body Weight; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Lenalidomide; Multiple Myeloma; Renal Insufficiency, Chronic

2023
Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.
    Clinical pharmacology in drug development, 2018, Volume: 7, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Body Weight; Clinical Trials as Topic; Creatinine; Female; Healthy Volunteers; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Myelodysplastic Syndromes; Young Adult

2018
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
    Experimental neurology, 2009, Volume: 220, Issue:1

    Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight; Cell Survival; Cytokines; Disease Models, Animal; Humans; Immunologic Factors; Lameness, Animal; Lenalidomide; Mice; Mice, Transgenic; Motor Neurons; Nerve Degeneration; Spinal Cord; Survival Rate; Thalidomide; Treatment Outcome

2009